Treatment Adherence in Patients with Ulcerative Colitis Is Dependent on the Formulation of 5-Aminosalicylic Acid

Background/Aims: It is unclear whether 5-aminosalicylic acid (5-ASA) formulation is associated with treatment adherence in ulcerative colitis (UC). Thus, we aimed to investigate the adherence rate after switching from 5-ASA tablets to granules. Methods: This prospective study included 121 UC outpatients treated using 5-ASA tablets. They were grouped based on choice: Group 1 (continued with tablets) and Group 2 (switched to granules without regimen change). Group 2 was further divided into Group 3 (returned to tablets) and Group 4 (continued with granules). The patients completed a self-administered questionnaire regarding the treatment. The primary endpoint was change in adherence after switching to granules. Results: Seventy-nine patients continued with tablets, while 42 patients switched to granules. The adherence rate to the tablet was not significantly different between Group 1 and 2 before switching. In Group 2, switching to granules did not affect adherence. However, in Group 4, adherence significantly improved after switching to granules. Group 3 showed no significant change in adherence before and after switching from tablets. Full-time work and difficulty taking tablets were significant predictors of continuing with granules in Group 4. Conclusion: Patients who continued with 5-ASA granules showed significantly increased adherence, suggesting that patient-tailored drug formulations improved treatment adherence.

• Publication year

  2018

• Venue

  Digestion

• Publication date

  2018-09-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000489878PMID 30179881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission

  2018cited by this paper
• Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis

  2014cited by this paper
• Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study

  2013cited by this paper
• Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study

  2013cited by this paper
• Long-Term Mesalamine Maintenance in Ulcerative Colitis: Which is More Important? Adherence or Daily Dose

  2013cited by this paper
• The Problem of Non-compliance with Drug Therapy

  2012cited by this paper
• Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review

  2010cited by this paper
• Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

  2009cited by this paper
• Antacid treatment of duodenal ulcer.

  2009cited by this paper
• Interventions for enhancing medication adherence.

  2008cited by this paper
• Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies

  2008cited by this paper
• Systematic review: adherence issues in the treatment of ulcerative colitis

  2006cited by this paper
• Review article: mode of action and delivery of 5‐aminosalicylic acid – new evidence

  2006cited by this paper
• Patient nonadherence to medication in inflammatory bowel disease.

  2004cited by this paper
• Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.

  2003cited by this paper
• Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease

  2003cited by this paper
• Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

  2001cited by this paper
• Compliance with anti‐ulcer medication during short‐term healing phase clinical trials

  1992cited by this paper
• The effect of prescribed daily dose frequency on patient medication compliance.

  1990cited by this paper
• How often is medication taken as prescribed? A novel assessment technique.

  1989cited by this paper
• [Ulcerative colitis].

  1958cited by this paper

• Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis.

  2025cites this paper
• Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany

  2025cites this paper
• Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition

  2024cites this paper
• Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey

  2023cites this paper
• A Quick Visible Spectrophotometry Approach For The Assessment Of Mesalazine In Pharmaceutical Preparations

  2023cites this paper
• Polymeric systems for colon-specific Mesalazine delivery in the intestinal bowel diseases management.

  2022cites this paper
• Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study.

  2022cites this paper
• Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation

  2020cites this paper
• Characteristics, Properties and Analytical/Bioanalytical Methods of 5-Aminosalicylic Acid: A Review

  2020cites this paper
• Modern use of 5-aminosalicylic acid compounds for ulcerative colitis

  2020cites this paper
• Shorter Relapse-Free Period after Leukocyte Removal Therapy in Younger than Older Patients with Ulcerative Colitis

  2018cites this paper